| Bioactivity | JBC117 is a novel anticancer lead compound targeting Pygo2 PHD. JBC117 can effectively antagonize the cell effect of β-catenin-dependent activity and inhibit the migration and invasion of cancer cells. JBC117 can induce apoptosis[1]. |
| Invitro | JBC117 (20 μM, 24 h) 可抑制结肠癌 (HCT116) 和肺癌 (A549) 的生长，IC50 值分别为 2.6 和 3.3 μM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> JBC117 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | JBC117 (20 mg/kg/天, 皮下注射, 连续 14 天) 在小鼠结肠癌和肺癌异种移植模型中具有抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1214531-21-1 |
| Formula | C28H30N2O3 |
| Molar Mass | 442.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ali F, et al. Logical design of an anti-cancer agent targeting the plant homeodomain in Pygopus2. Cancer Sci. 2016 Sep;107(9):1321-8. |